Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 27, 2024

Baseimmune secures funding for vaccine development

Baseimmune, a biotech firm specialising in artificial intelligence (AI)-driven vaccine development, has announced the successful closure of a £9m Series A funding round.

New investors MSD Global Health Innovation Fund and IQ Capital co-led Series A with existing investors taking part. Credit: Baseimmune.